Vitamin B12 deficiency is Symptoms of B12 deficiency include: rapid breathing shortness of breath headaches palpitations or fast heart rate indigestion, diarrhea, or loss of appetite blurry vision weakness or tiredness mouth ulcers or irritation cognitive changes, such as difficulty with memory, judgment, or understanding infertility Contact your doctor to discuss injections or supplements if you experience any conditions or risk factors related to vitamin B12 deficiency
Improved Glucose and Lipid Metabolism : Experimental studies demonstrate that suppression of NNMT activity with 5-Amino-1MQ correlates with improved glucose tolerance and reduced hepatic lipid accumulation
Those with diseases that affect the gut, such as Crohns disease or celiac disease, are also at risk ( Summary Those at greatest risk of vitamin B12 deficiency are vegans and vegetarians, who get little to no B12 from the diet
Handle using appropriate laboratory safety procedures
Antihistamines or creams may ease the symptoms
downstream mitochondrial biogenesis and fatty acid oxidation Form: Oral capsule, 250 mcg per capsule Frequency: Once to four times daily (split dosing) Cycle: 8 weeks on, 4 weeks off (educational framework) Storage: Sealed, room temperature, dry, light-protected Dosing Protocol Weeks 12: 250 mcg once daily, taken with a small amount of dietary fat to support absorption of the lipophilic compound Weeks 36: 500 mcg daily, split into morning and afternoon doses (12 hours apart where practical) Weeks 78: Optional escalation to 7501000 mcg daily, split across 34 doses Weeks 912: Off-cycle washout Timing: Dosing alongside meals containing fat is theorized to support absorption, but no oral pharmacokinetic data exist to confirm this Consistency: Maintain the same intra-day intervals across the cycle Storage Instructions Store the sealed bottle at room temperature (1525 C / 5977 F) Keep in a dry environment, away from direct light and humidity Do not refrigerate or freeze the capsules Replace the desiccant pack if included and visibly degraded Discard if capsules show discoloration, fusion, or shell breakdown Important Notes SLU-PP-332 has no human safety, efficacy, or pharmacokinetic data All efficacy data come from animal studies using a non-oral route The compound is investigational and is not approved by any regulatory body for human use Maintain detailed research logs of dosing, timing, and observations Discontinue immediately and document any unexpected observations Intended strictly for in vitro and research-model use
